Excitement at the EU Vet KOL Group Meeting: Celebrating Arthramid’s Success and Future Prospects
Copenhagen, March 12, 2025 – The recent EU Vet KOL Group meeting at Contura’s state-of-the-art facility brought together leading equine veterinarians from across Europe to discuss the remarkable benefits and…
Contura Animal Health Holdings acquires Innovative Medical Solutions
Contura Vet Limited, a wholly owned subsidiary of Contura Animal Health Holdings Limited, (“Contura Vet”), the owner and distributor of ArthramidVet®, an innovative veterinary medical product used for the treatment…
2023 North American Veterinary Regenerative Medicine Conference
Outrigger Kona Resort and Spa in Kona, Hawai’i September 22 – 24. Dr Jason Lowe presented his paper in a brief 15-minute talk. Histologic and cytologic changes in normal equine…
Arthramid Vet Expands its Presence in the Middle East
Dr Jason Lowe recently spent a few weeks in the Middle East, establishing relationships and sharing his knowledge with executives from some of the top Equine Care Centres and Veterinary…
New Joint Therapies in Animals
As veterinarians we understand the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is…
Japan Racing Association confirm no ban on the use of 2.5% polyacrylamide (PAAG) product Arthramid® Vet in Japan
Japan Racing Association (JRA) Anti-Doping Statement Regarding 2.5% PAAG Arthramid® Vet. The Japan Central Racing Association Feed and Drug Inspection Supervisory Committee Secretariat Anti-Doping Division, Horse Affairs Department have…
New technologies to aid in the treatment of osteoarthritis in dogs
Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases in dog populations, causing lameness and a loss of quality of life. It is estimated that 20-37% of dogs>…
Published Clinical Trial on the Efficacy of 2.5% PAAG Arthramid® Vet
This article is written for veterinarians, owners and trainers to summarise the major findings from a published study used for the listing of Arthramid Vet as a registered veterinary medicine in New Zealand and Australia. The…
Japan Racing Association (JRA)
Japan Racing Association (JRA) institute Laboratory for Racing Chemistry testing confirms Arthramid® Vet is free of Prohibited Substances in Japan Racing. To provide assurances to veterinarians in Japan, a representative…
New hydrogel technology to treat joint lameness in horses
New hydrogel technology, researched and adapted for veterinary use, offers a pioneering treatment for osteoarthritis in horses without an active pharmaceutical. Osteoarthritis (OA) is often cited as the most significant…
Pioneering treatment for arthritis may improve equine welfare and reduce wastage
Equine veterinarians have a range of options to treat lameness in horses caused by osteoarthritis (OA) and practitioners use all means at their disposal to ensure horses are exposed to the absolute…
2.5% iPAAG for managing intercarpal joint lameness – AAEP Presentation 2019
New treatments for osteoarthritis are always welcomed, and many times a cutting-edge product is presented at AAEP to advise practitioners of the possibilities to manage the equine athlete. It is…
